GENSIGHT DDR 2017 VA - ANNEXES (245/264)

GENSIGHT DDR 2017 VAGENSIGHT DDR 2017 VA - ANNEXES (245/264)GENSIGHT DDR 2017 VA - (1/264)GENSIGHT DDR 2017 VA - (2/264)GENSIGHT DDR 2017 VA - (3/264)GENSIGHT DDR 2017 VA - (4/264)GENSIGHT DDR 2017 VA - (5/264)GENSIGHT DDR 2017 VA - (6/264)GENSIGHT DDR 2017 VA - (7/264)GENSIGHT DDR 2017 VA - (8/264)GENSIGHT DDR 2017 VA - (9/264)GENSIGHT DDR 2017 VA - (10/264)GENSIGHT DDR 2017 VA - PERSONS RESPONSIBLE (11/264)GENSIGHT DDR 2017 VA - 1.1 NAME AND POSITION OF THE PERSON RESPONSIBLE FOR THE REGISTRATION DOCUMENT - 1.2 CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE REGISTRATION DOCUMENT - 1.3 NAME AND POSITION OF THE PERSON RESPONSIBLE FOR FINANCIAL INFORMATION (12/264)GENSIGHT DDR 2017 VA - STATUTORY AUDITORS (13/264)GENSIGHT DDR 2017 VA - 2.1 STATUTORY AUDITORS - 2.2 ALTERNATE STATUTORY AUDITORS (14/264)GENSIGHT DDR 2017 VA - SELECTED FINANCIAL INFORMATION (15/264)GENSIGHT DDR 2017 VA - 3.1 Selected Financial Information (16/264)GENSIGHT DDR 2017 VA - (17/264)GENSIGHT DDR 2017 VA - (18/264)GENSIGHT DDR 2017 VA - RISK FACTORS (19/264)GENSIGHT DDR 2017 VA - 4.1 RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS (20/264)GENSIGHT DDR 2017 VA - (21/264)GENSIGHT DDR 2017 VA - 4.2 RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF AND OBTAINING REGULATORY APPROVAL FOR OUR PRODUCT CANDIDATES (22/264)GENSIGHT DDR 2017 VA - (23/264)GENSIGHT DDR 2017 VA - (24/264)GENSIGHT DDR 2017 VA - (25/264)GENSIGHT DDR 2017 VA - (26/264)GENSIGHT DDR 2017 VA - (27/264)GENSIGHT DDR 2017 VA - (28/264)GENSIGHT DDR 2017 VA - (29/264)GENSIGHT DDR 2017 VA - (30/264)GENSIGHT DDR 2017 VA - 4.3 RISKS RELATED TO THIRD PARTIES (31/264)GENSIGHT DDR 2017 VA - (32/264)GENSIGHT DDR 2017 VA - (33/264)GENSIGHT DDR 2017 VA - 4.4 RISKS RELATED TO MANUFACTURING (34/264)GENSIGHT DDR 2017 VA - (35/264)GENSIGHT DDR 2017 VA - 4.5 RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCT CANDIDATES (36/264)GENSIGHT DDR 2017 VA - (37/264)GENSIGHT DDR 2017 VA - (38/264)GENSIGHT DDR 2017 VA - 4.6 RISKS RELATED TO OUR BUSINESS OPERATIONS (39/264)GENSIGHT DDR 2017 VA - (40/264)GENSIGHT DDR 2017 VA - (41/264)GENSIGHT DDR 2017 VA - (42/264)GENSIGHT DDR 2017 VA - (43/264)GENSIGHT DDR 2017 VA - (44/264)GENSIGHT DDR 2017 VA - 4.7 RISKS RELATED TO FINANCES AND TAXATION (45/264)GENSIGHT DDR 2017 VA - 4.8 LEGAL RISKS AND RISKS RELATED TO OUR INTELLECTUAL PROPERTY (46/264)GENSIGHT DDR 2017 VA - (47/264)GENSIGHT DDR 2017 VA - (48/264)GENSIGHT DDR 2017 VA - (49/264)GENSIGHT DDR 2017 VA - (50/264)GENSIGHT DDR 2017 VA - (51/264)GENSIGHT DDR 2017 VA - (52/264)GENSIGHT DDR 2017 VA - (53/264)GENSIGHT DDR 2017 VA - (54/264)GENSIGHT DDR 2017 VA - 4.9 MARKET RISKS (55/264)GENSIGHT DDR 2017 VA - 4.10 INSURANCE AND RISK MANAGEMENT (56/264)GENSIGHT DDR 2017 VA - (57/264)GENSIGHT DDR 2017 VA - (58/264)GENSIGHT DDR 2017 VA - (59/264)GENSIGHT DDR 2017 VA - 4.11 INTERNAL CONTROL AND RISK MANAGEMENT PROCEDURES (60/264)GENSIGHT DDR 2017 VA - 4.12 FINANCIAL RISK RELATED TO CLIMATE CHANGE (61/264)GENSIGHT DDR 2017 VA - (62/264)GENSIGHT DDR 2017 VA - INFORMATION ABOUT THE ISSUER (63/264)GENSIGHT DDR 2017 VA - 5.1 HISTORY AND DEVELOPMENT (64/264)GENSIGHT DDR 2017 VA - 5.2 INVESTMENTS (65/264)GENSIGHT DDR 2017 VA - (66/264)GENSIGHT DDR 2017 VA - BUSINESS OVERVIEW (67/264)GENSIGHT DDR 2017 VA - 6.1 OVERVIEW (68/264)GENSIGHT DDR 2017 VA - (69/264)GENSIGHT DDR 2017 VA - 6.2 OUR PRODUCT DEVELOPMENT PIPELINE - 6.3 OUR STRATEGY (70/264)GENSIGHT DDR 2017 VA - 6.4 GENE THERAPY IN THE EYE: A WELL-VALIDATED APPROACH (71/264)GENSIGHT DDR 2017 VA - 6.5 OUR LEAD PRODUCT CANDIDATE: GS010 FOR THE TREATMENT OF LHON (72/264)GENSIGHT DDR 2017 VA - (73/264)GENSIGHT DDR 2017 VA - (74/264)GENSIGHT DDR 2017 VA - (75/264)GENSIGHT DDR 2017 VA - (76/264)GENSIGHT DDR 2017 VA - (77/264)GENSIGHT DDR 2017 VA - 6.6 OUR SECOND PRODUCT CANDIDATE: GS030 FOR THE TREATMENT OF PHOTORECEPTOR DEGENERATION (78/264)GENSIGHT DDR 2017 VA - (79/264)GENSIGHT DDR 2017 VA - (80/264)GENSIGHT DDR 2017 VA - (81/264)GENSIGHT DDR 2017 VA - (82/264)GENSIGHT DDR 2017 VA - (83/264)GENSIGHT DDR 2017 VA - 6.7 LEVERAGING OUR PLATFORMS TO ADDRESS CENTRAL NERVOUS SYSTEM DISORDERS - 6.8 PHARMACO-ECONOMICS OF BLINDNESS AND VISUAL IMPAIRMENT (84/264)GENSIGHT DDR 2017 VA - 6.9 MANUFACTURING - 6.10 SALES AND MARKETING - 6.11 COMPETITION (85/264)GENSIGHT DDR 2017 VA - 6.12 GOVERNMENT REGULATION (86/264)GENSIGHT DDR 2017 VA - (87/264)GENSIGHT DDR 2017 VA - (88/264)GENSIGHT DDR 2017 VA - (89/264)GENSIGHT DDR 2017 VA - (90/264)GENSIGHT DDR 2017 VA - (91/264)GENSIGHT DDR 2017 VA - (92/264)GENSIGHT DDR 2017 VA - (93/264)GENSIGHT DDR 2017 VA - (94/264)GENSIGHT DDR 2017 VA - (95/264)GENSIGHT DDR 2017 VA - (96/264)GENSIGHT DDR 2017 VA - (97/264)GENSIGHT DDR 2017 VA - (98/264)GENSIGHT DDR 2017 VA - (99/264)GENSIGHT DDR 2017 VA - (100/264)GENSIGHT DDR 2017 VA - (101/264)GENSIGHT DDR 2017 VA - (102/264)GENSIGHT DDR 2017 VA - ORGANIZATIONAL CHART (103/264)GENSIGHT DDR 2017 VA - (104/264)GENSIGHT DDR 2017 VA - PROPERTY, PLANT AND EQUIPMENT (105/264)GENSIGHT DDR 2017 VA - 8.1 SIGNIFICANT EXISTING OR PLANNED PROPERTY, PLANT AND EQUIPMENT - 8.2 ENVIRONMENT AND SUSTAINABLE DEVELOPMENT (106/264)GENSIGHT DDR 2017 VA - (107/264)GENSIGHT DDR 2017 VA - (108/264)GENSIGHT DDR 2017 VA - (109/264)GENSIGHT DDR 2017 VA - (110/264)GENSIGHT DDR 2017 VA - (111/264)GENSIGHT DDR 2017 VA - (112/264)GENSIGHT DDR 2017 VA - OPERATING AND FINANCIAL REVIEW (113/264)GENSIGHT DDR 2017 VA - (114/264)GENSIGHT DDR 2017 VA - 9.1 Overview (115/264)GENSIGHT DDR 2017 VA - 9.2 Financial Operations Overview (116/264)GENSIGHT DDR 2017 VA - (117/264)GENSIGHT DDR 2017 VA - (118/264)GENSIGHT DDR 2017 VA - (119/264)GENSIGHT DDR 2017 VA - (120/264)GENSIGHT DDR 2017 VA - 9.3 Results of Operations (121/264)GENSIGHT DDR 2017 VA - (122/264)GENSIGHT DDR 2017 VA - (123/264)GENSIGHT DDR 2017 VA - (124/264)GENSIGHT DDR 2017 VA - CAPITAL RESOURCES (125/264)GENSIGHT DDR 2017 VA - 10.1 Overview - 10.2 Analysis of Cash Flow - 10.3 Funding Sources (126/264)GENSIGHT DDR 2017 VA - (127/264)GENSIGHT DDR 2017 VA - 10.4 Principal Uses of Cash (128/264)GENSIGHT DDR 2017 VA - (129/264)GENSIGHT DDR 2017 VA - (130/264)GENSIGHT DDR 2017 VA - RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES (131/264)GENSIGHT DDR 2017 VA - 11.1 Overview - 11.2 Research and Development Expenditures (132/264)GENSIGHT DDR 2017 VA - 11.3 Medical and Scientific Committee (133/264)GENSIGHT DDR 2017 VA - 11.4 Collaboration, Partnership and Related Agreements (134/264)GENSIGHT DDR 2017 VA - (135/264)GENSIGHT DDR 2017 VA - 11.5 Intellectual Property (136/264)GENSIGHT DDR 2017 VA - (137/264)GENSIGHT DDR 2017 VA - (138/264)GENSIGHT DDR 2017 VA - (139/264)GENSIGHT DDR 2017 VA - (140/264)GENSIGHT DDR 2017 VA - (141/264)GENSIGHT DDR 2017 VA - (142/264)GENSIGHT DDR 2017 VA - TREND INFORMATION (143/264)GENSIGHT DDR 2017 VA - 12.1 Most Significant Recent Trends Since the End of the Last Financial Year - 12.2 Information on Any Known Trends, Uncertainties, Demands, Commitments or Events That Are Reasonably Likely to Have a Material Effect on the Company’s Prospects (144/264)GENSIGHT DDR 2017 VA - PROFIT FORECASTS OR ESTIMATES (145/264)GENSIGHT DDR 2017 VA - (146/264)GENSIGHT DDR 2017 VA - ADMINISTRATIVE, MANAGEMENT AND SUPERVISORY BODIES AND SENIOR MANAGEMENT (147/264)GENSIGHT DDR 2017 VA - 14.1 Composition of Management and Supervisory Bodies (148/264)GENSIGHT DDR 2017 VA - (149/264)GENSIGHT DDR 2017 VA - (150/264)GENSIGHT DDR 2017 VA - (151/264)GENSIGHT DDR 2017 VA - (152/264)GENSIGHT DDR 2017 VA - 14.2 Conflicts of Interest (153/264)GENSIGHT DDR 2017 VA - (154/264)GENSIGHT DDR 2017 VA - COMPENSATION AND BENEFITS (155/264)GENSIGHT DDR 2017 VA - 15.1 Compensation and Benefits of Senior Executives (156/264)GENSIGHT DDR 2017 VA - (157/264)GENSIGHT DDR 2017 VA - (158/264)GENSIGHT DDR 2017 VA - 15.2 Directors’ Compensation (159/264)GENSIGHT DDR 2017 VA - (160/264)GENSIGHT DDR 2017 VA - 15.3 Share Warrants, Share Warrants for Founders, STOCK OPTIONS and FREE Shares Granted to Senior Executives and Directors (161/264)GENSIGHT DDR 2017 VA - (162/264)GENSIGHT DDR 2017 VA - 15.4 History of Allocation of Share Warrants, Share Warrants for Founders and stock options (163/264)GENSIGHT DDR 2017 VA - (164/264)GENSIGHT DDR 2017 VA - 15.5 Share Warrants, Share Warrants for Founders or Stock Options of the Company Granted to the Company’s Top Ten Employees - 15.6 History of Allocation of Free Shares (165/264)GENSIGHT DDR 2017 VA - 15.7 Benefits of Senior Executives - 15.8 Compliance of Total Executive Director Compensation with the Recommendations of MiddleNext Code - 15.9 Amount of Provisions Made or Recorded by the Company for the Payment of Pensions, Retirement Plans or Other Benefits (166/264)GENSIGHT DDR 2017 VA - BOARD PRACTICES (167/264)GENSIGHT DDR 2017 VA - 16.1 Terms of Office of Members of the Corporate Bodies and Management Bodies - 16.2 Information on Service Contracts Between Members of the Administrative and Management Bodies and the Company - 16.3 Committees of the Board of Directors (168/264)GENSIGHT DDR 2017 VA - (169/264)GENSIGHT DDR 2017 VA - 16.4 Statement Relating to Corporate Governance (170/264)GENSIGHT DDR 2017 VA - (171/264)GENSIGHT DDR 2017 VA - 16.5 Operating principals of the Board of Directors (172/264)GENSIGHT DDR 2017 VA - EMPLOYEES (173/264)GENSIGHT DDR 2017 VA - 17.1 Human Resources Management - 17.2 Corporate Social Responsibility (174/264)GENSIGHT DDR 2017 VA - 17.3 Shareholdings and Share Warrants or Share Warrants for Founders Held by Members of the Board of Directors and Senior Management - 17.4 Employee Shareholding Plan and Long-Term Incentive Plans - 17.5 Profit-Sharing Agreements and Incentive Schemes (175/264)GENSIGHT DDR 2017 VA - (176/264)GENSIGHT DDR 2017 VA - MAJOR SHAREHOLDERS (177/264)GENSIGHT DDR 2017 VA - 18.1 Allocation of share capital (178/264)GENSIGHT DDR 2017 VA - (179/264)GENSIGHT DDR 2017 VA - 18.2 Shareholders’ Voting Rights - 18.3 Control Structure (180/264)GENSIGHT DDR 2017 VA - 18.4 Shareholders’ Agreement - 18.5 Agreements Likely to Lead to a Change of Control - 18.6 Lock-Up Agreement - 18.7 Pledges on Company’s Shares (181/264)GENSIGHT DDR 2017 VA - (182/264)GENSIGHT DDR 2017 VA - RELATED PARTY TRANSACTIONS (183/264)GENSIGHT DDR 2017 VA - 19.1 Agreements with the Company’s Major Shareholders - 19.2 Transactions with Key Management Persons (184/264)GENSIGHT DDR 2017 VA - 19.3 Statutory Auditor’s Report on Regulated Agreements and Commitments for the Fiscal Year Ending December 31, 2017 (185/264)GENSIGHT DDR 2017 VA - (186/264)GENSIGHT DDR 2017 VA - FINANCIAL INFORMATION CONCERNING THE GROUP’S ASSETS AND LIABILITIES, FINANCIAL POSITION AND PROFITS AND LOSSES (187/264)GENSIGHT DDR 2017 VA - 20.1 Historical Financial Information (188/264)GENSIGHT DDR 2017 VA - (189/264)GENSIGHT DDR 2017 VA - (190/264)GENSIGHT DDR 2017 VA - (191/264)GENSIGHT DDR 2017 VA - (192/264)GENSIGHT DDR 2017 VA - (193/264)GENSIGHT DDR 2017 VA - (194/264)GENSIGHT DDR 2017 VA - (195/264)GENSIGHT DDR 2017 VA - (196/264)GENSIGHT DDR 2017 VA - (197/264)GENSIGHT DDR 2017 VA - (198/264)GENSIGHT DDR 2017 VA - (199/264)GENSIGHT DDR 2017 VA - (200/264)GENSIGHT DDR 2017 VA - (201/264)GENSIGHT DDR 2017 VA - (202/264)GENSIGHT DDR 2017 VA - (203/264)GENSIGHT DDR 2017 VA - (204/264)GENSIGHT DDR 2017 VA - (205/264)GENSIGHT DDR 2017 VA - (206/264)GENSIGHT DDR 2017 VA - (207/264)GENSIGHT DDR 2017 VA - (208/264)GENSIGHT DDR 2017 VA - (209/264)GENSIGHT DDR 2017 VA - (210/264)GENSIGHT DDR 2017 VA - (211/264)GENSIGHT DDR 2017 VA - (212/264)GENSIGHT DDR 2017 VA - (213/264)GENSIGHT DDR 2017 VA - (214/264)GENSIGHT DDR 2017 VA - (215/264)GENSIGHT DDR 2017 VA - 20.2 Date of Latest Financial Information - 20.3 Historical Financial Information for The Fiscal Years Ending December 31, 2015 and 2016 - 20.4 Dividend Policy - 20.5 Legal and Arbitration Proceedings - 20.6 Significant Change in Financial or Trading Position (216/264)GENSIGHT DDR 2017 VA - ADDITIONAL INFORMATION (217/264)GENSIGHT DDR 2017 VA - 21.1 Share Capital (218/264)GENSIGHT DDR 2017 VA - (219/264)GENSIGHT DDR 2017 VA - (220/264)GENSIGHT DDR 2017 VA - (221/264)GENSIGHT DDR 2017 VA - (222/264)GENSIGHT DDR 2017 VA - (223/264)GENSIGHT DDR 2017 VA - (224/264)GENSIGHT DDR 2017 VA - (225/264)GENSIGHT DDR 2017 VA - (226/264)GENSIGHT DDR 2017 VA - (227/264)GENSIGHT DDR 2017 VA - 21.2 Constitutive Documents and Bylaws (228/264)GENSIGHT DDR 2017 VA - (229/264)GENSIGHT DDR 2017 VA - (230/264)GENSIGHT DDR 2017 VA - (231/264)GENSIGHT DDR 2017 VA - (232/264)GENSIGHT DDR 2017 VA - MATERIAL CONTRACTS (233/264)GENSIGHT DDR 2017 VA - 22.1 Collaboration, Partnership and Related Agreements (234/264)GENSIGHT DDR 2017 VA - 22.2 In-License Agreements - 22.3 Manufacturing Agreement (235/264)GENSIGHT DDR 2017 VA - (236/264)GENSIGHT DDR 2017 VA - THIRD PARTY INFORMATION AND STATEMENT BY EXPERTS AND DECLARATIONS OF ANY INTEREST (237/264)GENSIGHT DDR 2017 VA - (238/264)GENSIGHT DDR 2017 VA - DOCUMENTS ON DISPLAY (239/264)GENSIGHT DDR 2017 VA - (240/264)GENSIGHT DDR 2017 VA - INFORMATION ON EQUITY INTERESTS (241/264)GENSIGHT DDR 2017 VA - (242/264)GENSIGHT DDR 2017 VA - GLOSSARY (243/264)GENSIGHT DDR 2017 VA - (244/264)GENSIGHT DDR 2017 VA - ANNEXES (245/264)GENSIGHT DDR 2017 VA - ANNEX 1. COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH-GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 - 1. BALANCE SHEET ASSETS - ANNEX 1 COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH-GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 (246/264)GENSIGHT DDR 2017 VA - (247/264)GENSIGHT DDR 2017 VA - 2. STATEMENTS OF INCOME (LOSS) (248/264)GENSIGHT DDR 2017 VA - 3. NOTES TO THE FINANCIAL STATEMENTS (249/264)GENSIGHT DDR 2017 VA - (250/264)GENSIGHT DDR 2017 VA - (251/264)GENSIGHT DDR 2017 VA - (252/264)GENSIGHT DDR 2017 VA - (253/264)GENSIGHT DDR 2017 VA - (254/264)GENSIGHT DDR 2017 VA - (255/264)GENSIGHT DDR 2017 VA - (256/264)GENSIGHT DDR 2017 VA - (257/264)GENSIGHT DDR 2017 VA - (258/264)GENSIGHT DDR 2017 VA - ANNEX 2 OTHER INFORMATION RELATING TO THE FINANCIAL STATEMENTS OF GENSIGHT BIOLOGICS S.A. PARENT COMPANY - ANNEX 2 OTHER INFORMATION RELATING TO THE FINANCIAL STATEMENTS OF GENSIGHT BIOLOGICS S.A. PARENT COMPANY (259/264)GENSIGHT DDR 2017 VA - ANNEX 3 STATUTORY AUDITOR’S REPORT ON THE COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 - ANNEX 3 STATUTORY AUDITOR’S REPORT ON THE COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 (260/264)GENSIGHT DDR 2017 VA - (261/264)GENSIGHT DDR 2017 VA - (262/264)GENSIGHT DDR 2017 VA - (263/264)GENSIGHT DDR 2017 VA - (264/264) ANNEXES 27 ANNEX 1 ANNEX 2 COMPANY’S ANNUAL FINANCIAL STATEMENTS OTHER INFORMATION RELATING TO (FRENCH-GAAP) FOR THE FISCAL YEAR ENDING THE FINANCIAL STATEMENTS OF DECEMBER 31, 2017 244 GENSIGHT BIOLOGICS S.A. PARENT COMPANY 257 1. BALANCE SHEET ASSETS 244 2. STATEMENTS OF INCOME (LOSS) 246 ANNEX 3 3. NOTES TO THE FINANCIAL STATEMENTS 247 STATUTORY AUDITOR’S REPORT ON THE COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 258 GENSIGHT BIOLOGICS – 2017 Registration Document –243